Lung tumors run their mitochondria hot: silencing one complex I gene collapses them — in lab models

Non-small cell lung cancer accounts for most lung cancer deaths, and its cells rewire energy production to sustain growth. Researchers at the Second Affiliated Hospital of Soochow University (Jiang, Yang, Chen and colleagues), publishing in npj Precision Oncology on October 19, 2026, asked whether one mitochondrial gene — NDUFS2, a core subunit of respiratory complex I — actively drives that rewiring.

What did the tumor data show?

Bioinformatics analysis of The Cancer Genome Atlas found NDUFS2 expression upregulated in NSCLC tissue versus normal lung, correlating with unfavorable clinicopathological features. Single-cell RNA sequencing showed NDUFS2 enriched in malignant cells across primary tumors and metastatic sites, and the team confirmed higher NDUFS2 in local patient tissues and multiple NSCLC cell lines.

What happened when NDUFS2 was switched off?

Silencing or knocking out NDUFS2 induced profound mitochondrial dysfunction and curtailed viability, proliferation, migration and invasion; adding glucose or the antioxidant N-acetylcysteine partially rescued the cells, tying the effect to energy failure and oxidative damage. Forcing NDUFS2 overexpression did the reverse — stronger mitochondrial function and more malignant behavior. In mouse xenografts, AAV-mediated NDUFS2 knockdown suppressed tumor growth, with ATP depletion, proliferation inhibition, Akt-mTOR inactivation and apoptosis in the tumor tissue. The study identifies NDUFS2 as a positive regulator of Akt-mTOR signaling.

Why is this not yet a lung cancer treatment?

Because complex I is essential in healthy tissue too — a drug that silences NDUFS2 everywhere would be expected to harm normal mitochondria, and no such drug has been tested in people. The evidence is bioinformatics, cell lines and mouse xenografts. Its value is directional: at least some lung tumors depend on mitochondrial hyperfunction, not just glycolysis, and that dependence is a testable vulnerability.

Where the evidence stands

• Established: NSCLC cells rewire energy metabolism, and complex I is essential to mitochondrial ATP production in healthy and malignant cells.
• Preliminary: In TCGA data, patient tissue, NSCLC cell lines and mouse xenografts (npj Precision Oncology, Oct 19, 2026), NDUFS2 was upregulated and enriched in malignant cells; silencing it caused mitochondrial dysfunction, ATP depletion and reduced growth/invasion in cells and suppressed xenograft growth, while overexpression enhanced malignant traits via Akt-mTOR.
• Absent: Any NDUFS2-targeting drug, human safety data, or evidence the target can be hit without harming healthy mitochondria.